Navigation Links
Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent
Date:6/7/2012

Berlin, Germany, June 7 2012: Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.

"Anti-TNFs, such as infliximab, adalimumab and etanercept have become the treatment of choice for patients with inflammatory rheumatic diseases who are uncontrolled on traditional DMARDs, but it is known that a side effect of these drugs is an increased risk of bacterial infections," said Ms. Helene Che, from Lapeyronie Hospital, France and lead author of the study. "This systematic review and meta-analysis demonstrates that careful monitoring of patients treated with anti-TNFs is required for early signs and symptoms of herpes zoster and raises the issue as to when vaccination against the virus should occur."

The study authors conducted a literature search in Medline, Embase, the Cochrane library and abstracts from ACR and EULAR congresses from 2006 to 2010. From the 657 articles, 134 congress abstracts, and 11 national registries included in the literature search, 22 articles and 28 abstracts met eligibility criteria and were included in the study. The meta-analysis included a total follow up of 124,966 patient years (PY) (74,198 PY in the biologics group and 50,768 PY in the DMARD group) across five registries.

Studies were included in the meta-analysis if they reported the respective incidences of herpes infection in anti-TNF and conventional DMARD treated patients. Incidence of severe herpetic infections (multidermatomal lesions, requiring hospitalisation or intravenous treatment) were excluded and reported when available.

Herpes zoster, also known as shingles, is a painful, blistering skin rash due to the varicella-zoster virus, the same virus that causes chickenpox . People are more likely to develop it if they are older than 60, had chickenpox before the age of one and have a compromised immune system due to medications or diseasei. Symptoms include one-sided pain, tingling or burning followed by a rash of small blisters, which eventually break, ulcer and dry upi. Other symptoms may include fever, chills, abdominal pain, swollen glands, difficulty moving muscles in the face, and drooping eyelidsi. Shingles is usually treated with antiviral medications to reduce pain and complications and corticosteroids to reduce swellingi. Pain from shingles can last for months or years, even though the infection normally lasts only two to three weeks. The virus can also cause temporary or permanent paralysis.*

Abstract Number: THU0368


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
2. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
3. Hear to see: New method for the treatment of visual field defects
4. Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment
5. Antioxidant shows promise as treatment for certain features of autism, Stanford study finds
6. Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
7. British experts update addiction treatment guidelines
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Correct treatment of common diabetic foot infections can reduce amputations
10. Biomarker predicts response to cancer treatment
11. First, do no harm: Study finds danger in standard treatment for a serious lung disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Gym Source, America’s leading retailer of premium ... East Hanover, New Jersey. , “We are elated to be opening this new showroom,” ... is designed to give clients a seamless and motivating shopping experience.” , Every fitness ...
(Date:1/16/2017)... ... ... Anybody who may be looking for a substance abuse rehabilitation program with ... a holistic treatment center for addiction located in Marne, MI. This video, which can ... and staff that visited the 2016 Recovery Palooza support event in nearby Grand Rapids. ...
(Date:1/16/2017)... IL (PRWEB) , ... January 16, 2017 , ... ... seating manufacturer Prairie Seating. Prairie’s award-winning Reflection® brand of custom seating systems has ... The acquisition provides Permobil with a platform for innovation and growth in the ...
(Date:1/16/2017)... St. Louis, MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware ... is here , This year’s influenza shot seems to be having no effect ... public area, at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... January 16, 2017 , ... In 1985, the ... high-level training standards to an international multidisciplinary group of healthcare treatment providers and ... way to further its mission at the grassroots level, iaedp launched MemberSHARE, an ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... -- Verathon ® Inc., a leading manufacturer and marketer of imaging ... Spectrum TM Single-Use video laryngoscopes. The new ... Light Reduction TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) Video ...
(Date:1/16/2017)... Jan. 16, 2017  Harrington Discovery Institute at ... – part of The Harrington Project for ... partnership Scholars selected in collaboration with Alzheimer,s Drug ... University of Oxford. Harrington Discovery ... to advance discoveries into new medicines that will ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 According ... Controller, Touchscreen Controller, Multi Display , Smart Display, Graphic LCD Controller), ... Forecast to 2022", published by MarketsandMakets, the market is expected to grow ... 2022, at a CAGR of 9.68% between 2016 and 2022. ... ...
Breaking Medicine Technology: